Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The transcript discusses various business segments. We need to look for any statement about deal sizes, contract sizes, project sizes, etc., escalating over time. Key points: In Individual Retirement, they mention strong sales, but not about size of individual deals. In Group Retirement, they mention new plan acquisitions, but not about size. In Institutional Markets, they mention pension risk transfer transactions totaling $1.3 billion in Q4, but that's a total, not necessarily larger than before. They also mention a robust pipeline. But no comparison to past sizes. In Life Insurance, they talk about improving mix, but not about deal size. The question asks specifically about "successive engagements of the same kind" coming in at progressively larger size. There is no mention of average deal size increasing, or that new contracts are larger than previous ones. The only mention of a large transaction is the $1.3 billion PRT in Q4, but that's not framed as part of an upward drift. They say "we closed pension risk transfer transactions totaling $1.3 billion in the fourth quarter." No comparison to prior quarters or years. They also say "we continue to see a robust pipeline" but that's about future, not about size escalation. Thus, no evidence of escalating unit size. Answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.